Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Regeneron Pharmaceuticals, Inc.
REGNHealth technology
$72.8B
Market Cap
Shariah Analysis
Passed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Regeneron Pharmaceuticals, Inc. appears to be Passed.
Business Activity
FYE 2024
Non-Permissible Income (<5%)4.70%
Non-Permissible
$711.4M
Total Income
$15B
Revenue Breakdown
Net product sales
$7.6B
Collaboration revenue
$6.1B
Other revenue
$515M
Unrealized gains (losses) on equity securities, net
Non-Operating
$117.7M
Interest income
Non-Operating
$711.4M
Non-Compliant: $711.4M
Other
Non-Operating
$15.8M
Financial Screening
FYE 2024
Cash (<30%)11.61%
Non-Shariah Cash Items
Cash And Cash Equivalents$2.5B
Other Short Term Investments$6.5B
Liabilities (<30%)3.48%
Non-Shariah Liabilities
Long Term Debt$2B
Long Term Capital Lease Obligation$720M
Market Data
Exchange
NASDAQ
CurrencyUSD
CountryUnited States
Last Updated2026-01-11
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
NASDAQ
